DCGI Current Affairs - 2020

Russia to sell COVID-19 vaccines to India

On September 16, 2020, Russia’s sovereign wealth fund agreed to supply 100 million doses of COVID-19 vaccine, Sputnik-V to an Indian drug company Dr Reddy’s Laboratories. The deal has been finalized after the Russian Direct Investment Fund (RDIF) reached agreements with the Indian manufacturer to produce 300 million doses of COVID-19 vaccines to India. What Read More…

SII directed to suspend recruitment for Oxford vaccine trial

Drugs Controller General of India (DCGI) which is country’s apex drug regulator has directed Serum Institute of India SII to suspend the new recruitments which were about to happen for recent phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine till further orders. Why the SII is asked to suspend recruitment for vaccine Read More…

India to start trial of Oxford COVID-19 vaccine

India’s top drug regulatory body DCGI (The Drugs Controller General of India) finally gave green signal to Serum Institute of India (SII) for conducting phase II and III clinical trials of Astra Zeneca vaccine developed by the Oxford University against coronavirus disease. The approval came after scrutiny was done based on the recommendations of the Read More…

Japan approves Dexamethasone as COVID-19 Treatment

The Japanese Government recently approved Dexamethasone as a second treatment of COVID-19. The approval came in after Britain showed that the drug reduced death rates in COVID-19 patients. Highlights Dexamethasone has been approved for treatment along with Remdesivir. A clinical trial of UK proved that Dexamethasone as the first drug saved lives of COVID-19. India Read More…

CSIR: Clinical Trial of “Sepsivac” drug on critically ill COVID-19 patients

On April 22, 2020, the Council of Scientific and Industrial Research announced that it is to go for clinical trials on critically ill COVID-19 patients. Background The Drugs Controller General of India recently approved the trial of “Sepsivac”. The drug is available commercially. With the DCGI approving the drug, CSIR is to start clinical trials Read More…